Overview
Intracellular delivery remains a persistent challenge in drug delivery, gene editing, and biotechnology. Pharmaceutical and biotech companies lose valuable opportunities when promising drugs and biologics cannot reach their intended targets inside cells, limiting product effectiveness and market potential. This technology introduces a revolutionary molecular feature that allows for a wide range of therapeutic and research agents to cross cell membranes, unlocking access to previously unreachable targets.

The Opportunity
Developed by OSU researchers, this proprietary platform enables a broad range of therapeutic and research agents to cross cell membranes. This innovation can empower organizations to develop new classes of medicines and research tools and expand into high-growth markets. By overcoming a long-standing delivery barrier, companies can accelerate product development, improve patient outcomes, and capture new revenue streams—while contributing to solutions that address critical health challenges worldwide.

Key Advantages

• Enhanced Bioavailability: Increases cellular uptake and intracellular access, opening new markets for drugs and biologics previously limited by delivery barriers.
• Tunable Performance: Adjustable delivery efficiency for specific cargos and cell types, maximizing therapeutic impact.
• Streamlined Integration: Compact design and post-synthetic compatibility simplify adoption into existing workflows and products.

Transform Your Product Strategy
Adopting this technology can position your organization to lead in precision medicine, gene editing, and advanced biologics. Empower your teams to innovate faster, reach new patient populations, and maximize the commercial impact of your pipeline.

Contact us today to explore licensing or collaborative development opportunities.